Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

Inclusion Criteria

• •Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \[VALG\] staging system)
• •No prior systemic treatment for ES-SCLC
• •18-80 years old, or more than 10 months of expected natural survival;
• •Eastern Cooperative Oncology Group performance status of 0 or 1 or 2
• •Measurable disease, as defined by RECIST v1.1 Adequate hematologic and end organ function
• •Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
• •The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent